Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Dr. Kabanov is a Distinguished Professor, Director, Center for Nanotechnology in Drug Delivery, and Co-Director, Carolina Institute for Nanomedicine, University of North Carolina at Chapel Hill since July 2012. Prior to this appointment he served for nearly 18 years at the University of Nebraska Medical Center where he was a Parke-Davis Professor of Pharmaceutical Sciences and Director of the Center for Drug Delivery and Nanomedicine, which he founded in 2004. Dr. Kabanov received Ph.D. degree in chemical kinetics and catalysis in 1987 at Moscow State University, USSR. Dr. Kabanov published over 250 scientific papers, and has over 100 patents worldwide. His work was cited over 20,000 times (Hirsh index 77) and he is named the Thomson Reuters 2014 Highly Cited Researcher in pharmacology and toxicology. His cumulative research support in academia has been over $95 M total. His inventions attracted nearly $60 M corporate investment and industry-sponsored R&D funding. He founded Nanomedicine and Drug Delivery Symposium (NanoDDS) series (2003-) and co-chaired Gordon Research Conference on Drug Carriers in Medicine and Biology (2006). He is a recipient of Lenin Komsomol Prize (1988), NSF Career Award (1995), University of Nebraska ORCA Award (2007), UNMC Scientist Laureate (2009), Russian "Megagrant" (2010), elected member of Academia Europaea (2013), and American Institute for Medical and Biological Engineering (AIMBE)'s College of Fellows (2014) among other distinctions. He was a director of US NIH Center of Biomedical Research Excellence (CoBRE) "Nebraska Center for Nanomedicine" (2008-2012), and is a Director of Laboratory of Chemical Design of Bionanomaterials, which he founded at Moscow State University in 2010 with the Megagrant support.
Dr. Kabanov’s research focuses on polymeric micelles, DNA/polycation complexes, block ionomer complexes and nanogels for delivery of small drugs, nucleic acids and proteins that considerably influenced current ideas and approaches in drug delivery and nanomedicine. His work led to first-in-man polymeric micelle drug (SP1049C) to treat cancer, which successfully completed Phase II clinical trial and is under further evaluation. He co-founded Supratek Pharma, Inc. (Montreal, Canada), which develops therapeutics for cancer and Neuro10-9, Inc. (Chapel Hill, NC) focusing on diseases of the central nervous system (CNS).
Yuling Zhao, Matthew J. Haney, Vivek Mahajan, Benjamin C. Reiner, Anna Dunaevsky, R. Lee Mosley, Alexander V. Kabanov, Howard E. Gendelman and Elena V. Batrakova
Research Article: J Nanomed Nanotechnol 2011, S4-003